• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

作者信息

Nicot Christophe

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

出版信息

Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.

DOI:10.1186/s12943-025-02423-6
PMID:40784877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335760/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfd5/12335760/4fcc9cf514e0/12943_2025_2423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfd5/12335760/4fcc9cf514e0/12943_2025_2423_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfd5/12335760/4fcc9cf514e0/12943_2025_2423_Fig1_HTML.jpg

相似文献

1
CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.环状RNA适配体靶向IGF2BP2以克服获得性BETi耐药性。
Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.
2
A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.一种环状RNA通过拮抗TNBC中IGF2BP2介导的c-MYC翻译来克服对BET抑制剂的获得性耐药。
Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.
3
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.靶向β-catenin-TCF7L2-JMJD6-c-Myc 轴克服 BET 抑制剂耐药性的作用机制和疗效。
Blood. 2020 Apr 9;135(15):1255-1269. doi: 10.1182/blood.2019002922.
4
Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.乳酸利用使代谢逃逸能够抵抗急性髓系白血病中的 BET 抑制。
Cancer Res. 2024 Apr 1;84(7):1101-1114. doi: 10.1158/0008-5472.CAN-23-0291.
5
Concurrent targeting of MAP3K3 and BRD4 by overcomes acquired resistance to BET inhibitors in neuroblastoma cells.通过同时靶向MAP3K3和BRD4克服神经母细胞瘤细胞对BET抑制剂的获得性耐药。
Mol Ther Nucleic Acids. 2021 May 11;25:83-92. doi: 10.1016/j.omtn.2021.05.001. eCollection 2021 Sep 3.
6
Circ_0000847 promotes the migration, invasion, and EMT process in colorectal cancer through binding to IGF2BP2 to enhance IGF2 mRNA stability.环状RNA_0000847通过与胰岛素样生长因子2结合蛋白2（IGF2BP2）结合以增强IGF2信使核糖核酸（mRNA）稳定性，从而促进结直肠癌的迁移、侵袭及上皮-间质转化过程。
Med Oncol. 2025 Aug 22;42(10):436. doi: 10.1007/s12032-025-02877-0.
7
circDHX33 suppresses glycolysis, malignant proliferation, and metastasis in prostate cancer by interacting with RNA-binding protein IGF2BP2 to destabilize its protein.环状DHX33通过与RNA结合蛋白IGF2BP2相互作用使该蛋白不稳定，从而抑制前列腺癌中的糖酵解、恶性增殖和转移。
Cytotechnology. 2025 Apr;77(2):56. doi: 10.1007/s10616-025-00718-6. Epub 2025 Feb 6.
8
Circ_0006646 Promotes the Progression of Osteoarthritis via Upregulating CDH11 Expression in an IGF2BP2-Dependent Manner.Circ_0006646通过以IGF2BP2依赖性方式上调CDH11表达促进骨关节炎进展。
Kaohsiung J Med Sci. 2025 Aug;41(8):e70031. doi: 10.1002/kjm2.70031. Epub 2025 May 19.
9
Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.靶向 CCR2 巨噬细胞的 BET 抑制剂克服了卵巢癌对抗 VEGF 治疗的适应性耐药。
J Cancer Res Clin Oncol. 2022 Apr;148(4):803-821. doi: 10.1007/s00432-021-03885-z. Epub 2022 Jan 30.
10
Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.含溴结构域蛋白BRD4在有丝分裂中发生超磷酸化。
Cancers (Basel). 2020 Jun 20;12(6):1637. doi: 10.3390/cancers12061637.

本文引用的文献

1
A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.一种环状RNA通过拮抗TNBC中IGF2BP2介导的c-MYC翻译来克服对BET抑制剂的获得性耐药。
Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.
2
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.溴结构域和末端结构域（BET）蛋白：生物学功能、疾病和靶向治疗。
Signal Transduct Target Ther. 2023 Nov 6;8(1):420. doi: 10.1038/s41392-023-01647-6.
3
Why rings of RNA could be the next blockbuster drug.
为何RNA环可能成为下一个重磅药物。
Nature. 2023 Oct;622(7981):22-24. doi: 10.1038/d41586-023-03058-7.
4
BET proteins: Biological functions and therapeutic interventions.BET 蛋白：生物学功能与治疗干预。
Pharmacol Ther. 2023 Mar;243:108354. doi: 10.1016/j.pharmthera.2023.108354. Epub 2023 Feb 3.
5
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.BCL6 赋予 KRAS 突变型非小细胞肺癌对 BET 抑制剂的耐药性。
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI133090.
6
Screening for functional circular RNAs using the CRISPR-Cas13 system.利用 CRISPR-Cas13 系统进行功能性环状 RNA 的筛选。
Nat Methods. 2021 Jan;18(1):51-59. doi: 10.1038/s41592-020-01011-4. Epub 2020 Dec 7.
7
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.DUB3 通过去泛素化 BRD4 促进 BET 抑制剂耐药和癌症进展。
Mol Cell. 2018 Aug 16;71(4):592-605.e4. doi: 10.1016/j.molcel.2018.06.036. Epub 2018 Jul 26.
8
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.前列腺癌相关的SPOP突变通过稳定BRD4赋予对BET抑制剂的抗性。
Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.
9
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.三阴性乳腺癌对BET溴结构域抑制剂的反应与耐药性
Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.
10
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.转录可塑性促进对BET抑制的原发性和获得性耐药。
Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14.